Early Stage Partners
VC Fund
Cleveland, United States
Early Stage Partners is a Midwest-based investment firm that provides early-stage venture capital financing to entrepreneurial companies.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 12%
- Fund size:
- $55M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Early Stage Partners invests in
Stages Early Stage Partners invests in
Countries Early Stage Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
|
|||
|
|
|||
|
|
|||
|
|
Investment Focus
Industry
- Software 8 (20%)
- Health Care 8 (20%)
- Biotechnology 7 (17%)
- Medical Device 7 (17%)
- SaaS 5 (12%)
Stage
- Series B 13 (32%)
- Series A 12 (29%)
- Series C 8 (20%)
- Funding Round 4 (10%)
- Series D 3 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Charlie MacMillan
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Jim Petras
Managing Partner
|
Managing Partner | Total investments: 7 | Find email | |
|
Mike Bunker
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Jim McConoughey
Active Fund Manager
|
Active Fund Manager | Total investments: 0 | Find email | |
|
Jonathan Murray
Managing Director and Co-Founder
|
Managing Director and Co-Founder | Total investments: 11 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | Private Equity / Aug 07, 2025 | |
|
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $8.3M / Series B / Mar 13, 2017 | |
|
|
OnShift delivers cloud-based human capital management software and proactive services to solve everyday workforce challenges in healthcare. Our suite of products for hiring, scheduling and employee engagement drives quality care, lower costs and higher performance by empowering providers to staff consistently and efficiently. Intuitive design,predictive analytics and customer success management are why thousands of post-acute care and senior living organizations rely on OnShift. | $18M / Series D / Apr 13, 2016 | |
|
|
Amplifinity develops referral software that automates the referral tracking and management of B2B customer and partner referral programs. Amplifinity's referral platform provides a steady flow of leads from referral sources you partner with including customers, non-reseller partners, agents, consultants, and more. Amplifinity automates thetracking and management of referrals and the handling of reward fulfillment and variable incentive structures. A Salesforce integration drives sales referral productivity. Companies like ADP, LogMeIn, and Citrix use Amplifinity to automate their referral programs and enable high-quality acquisition while providing an engaging experience for their partners.Amplifinity was formed in 2008 and is based in Ann Arbor, Michigan, USA. | $7M / Series B / Mar 18, 2014 | |
|
|
OnShift delivers cloud-based human capital management software and proactive services to solve everyday workforce challenges in healthcare. Our suite of products for hiring, scheduling and employee engagement drives quality care, lower costs and higher performance by empowering providers to staff consistently and efficiently. Intuitive design,predictive analytics and customer success management are why thousands of post-acute care and senior living organizations rely on OnShift. | $7M / Series C / Feb 03, 2014 | |
|
|
CardiOx Corporation develops and offers systems that measure and monitor cardiac output, total circulating blood volume, and endogenous blood ammonia levels. | $4M / Jan 03, 2013 | |
|
|
Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials.Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine. | $22.2M / Series B / Jul 16, 2012 | |
|
|
OnShift delivers cloud-based human capital management software and proactive services to solve everyday workforce challenges in healthcare. Our suite of products for hiring, scheduling and employee engagement drives quality care, lower costs and higher performance by empowering providers to staff consistently and efficiently. Intuitive design,predictive analytics and customer success management are why thousands of post-acute care and senior living organizations rely on OnShift. | $4.5M / Series B / May 02, 2012 | |
|
|
LineStream Technologies provides control technology and software solutions that improve the performance of automated products and processes. Its software into products ranging from washing machines to sophisticated manufacturing equipment. LineStream Technologies was founded in 2008 and headquartered in Cleveland, Ohio. | $5M / Series B / Mar 12, 2012 | |
|
|
CytoPherx (formerly Nephrion) clinical stage medical device company addressing inflammation-based diseases and conditions. The company’s products are custom configurations of a proprietary selective cytopheresis-based inflammation modulating system. | $34M / Series C / Jan 04, 2012 | |
| See all 41 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Early Stage Partners invest in?
Early Stage Partners invests primarily in Software, Health Care and Biotechnology startups, most often at Series B and Series A stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Early Stage Partners?
Public channels for Early Stage Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Early Stage Partners?
The team at Early Stage Partners includes Charlie MacMillan (Chief Financial Officer), Jim Petras (Managing Partner) and Mike Bunker (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!